Phase 3 Lung Cancer Trial, Not Yet Recruiting NCT07242274 Sponsor: Jemincare Condition: Lung Cancer
Back to Lung Cancer

Phase 3 Lung Cancer Trial, Not Yet Recruiting

NCT07242274
Not Yet Recruiting Phase 3

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults aged 18 years or older.
  • People who have been diagnosed with non-small cell lung cancer (a specific type of lung cancer) confirmed through a tissue or cell sample test.
  • People whose cancer has already been treated with at least one previous treatment plan that included both a platinum-based chemotherapy and a type of immunotherapy drug known as a PD-1/PD-L1 inhibitor, and that treatment did not work or stopped working.
  • People who have at least one area of cancer in the body that is measurable using standard imaging guidelines (confirm with trial site).

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose cancer is driven by certain other known genetic mutations or gene rearrangements for which specific targeted treatments already exist.
  • People who have previously received any treatment that specifically targets the KRAS G12C gene mutation.
  • People who have previously received a chemotherapy drug called docetaxel for advanced or metastatic disease.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026

Contact this trial

Principal Investigator: Jie Wang, Doctor, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

Phone: +86 15720614080

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 3
Sponsor
Jemincare
Registry
ClinicalTrials.gov
Start date
31 December 2025
Est. completion
31 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

PFS

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov